Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | RARA | P10276 | 1/20 | 0.30 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.30 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
| ▸ | RARG | P13631 | 1/20 | 0.30 |
| ▸ | GOT1 | P17174 | 1/20 | 0.30 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL549007 | 0.92 | HDAC11 (0.37) | HDAC11MEN1NR1I2LMNAPGR | |
| SCHEMBL548855 | 0.89 | HDAC11 (0.36) | HDAC11MEN1NR1I2LMNAPGR | |
| SCHEMBL548673 | 0.88 | HDAC11 (0.36) | HDAC11MEN1NR1I2LMNAPGR | |
| SCHEMBL549953 | 0.81 | HDAC11 (0.30) | HDAC11 | |
| SCHEMBL549838 | 0.80 | — | — | |
| SCHEMBL548815 | 0.80 | KMT2A (0.39) | HDAC11MEN1NR1I2LMNAPGR | |
| SCHEMBL547739 | 0.80 | KMT2A (0.39) | HDAC11MEN1NR1I2LMNAPGR | |
| SCHEMBL548773 | 0.79 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL549856 | 0.79 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL549104 | 0.79 | ALDH1A1 (0.38) | MEN1RARAKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110614-B2 | Adamantane derivative, method for producing the same, and resin composition containing adamantane derivative | IDEMITSU KOSAN CO., LTD. (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20100056663-A1 | ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE | IDEMITSU KOSAN CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2090563-A1 | ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE | IDEMITSU KOSAN COMPANY LIMITED (JP) | 2009-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056663-A1 | ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE | ARCN1, RTN3, CHRNA3 | HDAC11 4520/4885MEN1 3412/4885NR1I2 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.